Provention Investor Sues To Stop $2.9B Sanofi Merger
A Provention Bio Inc. investor has filed a lawsuit seeking to delay the biopharmaceutical company's pending $2.9 billion equity merger with Sanofi SA until it explains the deal's financial justification and...To view the full article, register now.
Already a subscriber? Click here to view full article